Morningstar Inc (MORN) is Trading Higher on Unusual Volume for January 14

Equities Staff |

Morningstar Inc (MORN) experienced unusually high volume on Jan. 14, as the stock gained 1.95% to a closing price of $77.11. The stock saw 142,449 shares trade hands over the course of the day on 1,246 trades. Given that the stock’s average daily volume over the last month has been 90,571 shares a day, this represents a pretty substantial spike over the norm.

Morningstar Inc has a P/B ratio of 5.02. It also has a P/E ratio of 27.1. The stock has traded between $86.88 and $62.25 over the last 52-weeks, its 50-day SMA is now $79.94, and its 200-day SMA $79.27.

Morningstar Inc is a provider of independent investment research in North America, Europe, Australia, and Asia. It offers products and services for financial advisors, asset managers, retirement plan providers and sponsors, and individual investors.

Headquartered in Chicago, IL, Morningstar Inc has 3,830 employees and is currently under the leadership of CEO Joe Mansueto.

For a complete fundamental analysis analysis of Morningstar Inc, check out’s Stock Valuation Analysis report for MORN. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…